AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2020
Oct 5, 2020
35172_dirs_2020-10-05_8ea06a21-a8a5-46b0-89b5-d3b456319ccd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2020-10-02
Reporting Person: Young David (Director, Chief Executive Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants (Right to Buy) | $19.068 | 2021-06-29 | Common Stock (3147) | Direct | |
| Warrants (Right to Buy) | $19.068 | 2021-06-29 | Common Stock (20309) | Indirect | |
| Warrants (Right to Buy) | $19.068 | 2021-06-29 | Common Stock (15734) | Indirect | |
| Warrants (Right to Buy) | $17.164 | 2021-05-25 | Common Stock (14731) | Indirect |
Footnotes
F1: This amended Form 3 is being filed to add the grant date/exercise date of the warrant issued to the reporting person.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15